ZHBIO(SZ:300653)2023-04-14 08:10Group 1: Company Performance and Financials - The revenue from Jiangsu Chuangying's implant代理 in 2022 was approximately ¥30,695,664.35, accounting for over 7% of total revenue [2] - The sales revenue of oral repair membranes in 2022 was ¥20,717.87 million [4] - The decline in performance in Q4 2022 was primarily due to the impact of domestic COVID-19 on the oral implant sector [2] Group 2: Product Development and Sales - The active biological bone product has been developed over 14 years and is the first of its kind to receive certification in China, which is expected to open up growth opportunities for the company [6] - The sales of active biological bone have commenced, but actual sales figures will depend on future market promotion effectiveness [6] - The company is actively expanding its sales layout for active biological bone across various provinces [5] Group 3: Market Strategy and Competition - The company is monitoring the centralized procurement policies for oral-related products and will respond proactively [1] - The company has successfully participated in centralized procurement in six provinces for its absorbable hard brain (spinal) membrane, maintaining a record of winning all bids [6] - The company holds a strong advantage in the oral channel and is focused on leveraging past successful experiences to maintain its market position [6]